Mélanie retweeted
Does local treatment of the primary tumour still add value in #mHSPC patients receiving ARPIs? Our latest expert opinion examines the evidence, ongoing controversies and future directions in the intensification era.
Article here: tandfonline.com/doi/full/10.…
#Genitourinary #Prostate
Mélanie retweeted
More about #RareHistology GU tumors at @IstTumori: update on academic trials by @MelClaps and multidisciplinary discussion because rare doesn’t mean less important.
#ClinicalResearch #Oncology #Genitourinary #ScientificEvent #ControversiesinGU2026
Mélanie retweeted
Ready for @ASCO #GU23!
Here's Meet-URO selection of the hot topics and key presentation.
Looking forward to exciting data presented in San Francisco.
Congrats to the @meeturoIT group for the selected works!
ALT Meet-URO selection of the hot topics and key presentation at ASCO GU 2023
Mélanie retweeted
COSMIC313 cabo/ipi/nivo vs ipi/nivo in 1st line RCC. ⬆️ FU & ⬆️ numbers show continued strong PFS signal:HR 0.74.Exploratory analysis show benefit for triplet mainly in intermediate risk .This is not due to ⬇️ drug exposure. Maybe VEGF treatment ⬇️ active in poor risk #GU23
Mélanie retweeted
Dr Mélanie Claps, @IstTumori GU Cancers Unit, about👇
Multicenter phase2⃣ single arm study of #cabozantinib in Pts w/ advanced or unresectable #renalcellcarcinoma pre-treated w/ one immune-checkpoint inhibitor ➡️ The BREAKPOINT trial (Meet-Uro trial 03)
journals.sagepub.com/doi/ful…
Mélanie retweeted
@gippo27 @MelClaps @ChiaraPircher @pierangelasepe @UgoDeGiorgi @DrIacovelli @elena_verzoni @meeturoIT et al
#GUcancers #kcsm
xitter.cf/TumoriJ/status/1619606…
Dr Mélanie Claps, @IstTumori GU Cancers Unit, about👇
Multicenter phase2⃣ single arm study of #cabozantinib in Pts w/ advanced or unresectable #renalcellcarcinoma pre-treated w/ one immune-checkpoint inhibitor ➡️ The BREAKPOINT trial (Meet-Uro trial 03)
journals.sagepub.com/doi/ful…